rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

Guru Terug naar discussie overzicht

***** GNBT *******

3.572 Posts
Pagina: «« 1 ... 143 144 145 146 147 ... 179 »» | Laatste | Omlaag ↓
  12. [verwijderd] 29 juni 2007 19:52

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    dank je zwaluw, ik heb er vroeger als kind gewoond, tsi hier molto bella...en als generex straks op 10$ of hoger staat koop ik hier echt een huis :)

    de huizen zijn tegenwoordig heel duur hier, veel rijke Milanezen hebben hier hun buitenhuis tegenwoordig....maar ja dat zijn wij straks ook.
    Stel je eens voor oralin op de markt ! dan praten we echt dik boven 10$
  16. [verwijderd] 4 juli 2007 12:34

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Worcester company working on an oral diabetes spray
    By Aaron Wasserman
    Article Launched: 07/01/2007 10:03:52 AM EDT


    The possibility of receiving diabetes treatment without a syringe took another step forward this week, as the biotechnology company developing a product that delivers insulin orally said it is nearing the third phase of its clinical trial.

    Generex Biotechnology Corp. of Toronto has been developing the product, Oral-lyn, which delivers insulin to patients via a spray that is absorbed through the mouth's inner lining, for about the past decade.

    Anna Gluskin, the company's president and chief executive officer, said part of Oral-lyn's potential success lies in its ability to let diabetics discard their insulin syringe and be more discreet about treatment.

    "The patient can use this device in public because nobody would even know what they're doing," she said in a telephone interview. "This is crucially important for the patient with diabetes because they don't want to advertise their condition."

    Generex now has regulatory approval for Oral-lyn in Ecuador only. Gluskin said approval from the federal Food and Drug Administration is at least two years away, though entry into other major markets is closer. Its new six-month trial, expected to start before the end of the year, will test 750 patients with Type 1 diabetes in the U.S., Canada and Europe.

    A Generex subsidiary, Antigen Express Inc. of Worcester, is in the early stages of developing a therapeutic vaccine for diabetes treatment, among other products, according to its president, Dr. Eric von Hofe. Generex is developing the spray technology for other applications as well.

    A few other pharmaceutical companies have also been developing other forms of oral insulin delivery. Exubera, a Pfizer product that delivers insulin through an inhaler, received the FDA's approval last year.

    Dr. Richard A. Jackson, a senior physician at the Joslin Diabetes Center of Boston, said a chief concern in developing oral insulin products is ensuring dosage accuracy. Insulin levels are especially sensitive and needles have proven to deliver accurate rations, he explained.

    "Small variances in the dosing and the speed of absorption is more important for insulin than other things. If absorption through the mouth varies by 15 percent, that's a lot," he said, adding he has not specifically reviewed Oral-lyn's efficiency. "It's whether they can achieve the accuracy and be consistent about how much is absorbed in the mouth."

    Jackson added insulin pens are a less painful form of medication delivery, creating another hurdle for oral products.

    Gluskin said Generex has carefully considered dosage consistency for Oral-lyn's hardware, and developed a system that essentially delivers one unit of insulin per puff. Oral-lyn's device is small enough to fit in a pocket and can be carried at room temperature.

    Generex's stock price -- though based in Toronto, the company is incorporated in the U.S. -- closed at $1.77 on Friday, about where it has been for the past two weeks.

    But the company received a noticeable boost earlier this month when the private investment bank Rodman & Renshaw LLC of New York gave Generex's stock an 18-month price target of $6.00. The bank's report projected $600 million in revenues from Oral-lyn by 2013.

    "Our analysis indicates that Generex's oral insulin, Oral-lyn, could be a significant player in the non-injectable insulin market," a Rodman & Renshaw analyst reported.

    Gluskin also argued that the competitor Exubera -- and similar products in development -- are less desirable than Oral-lyn because their inhaled delivery of insulin is more harmful to the pulmonary system than Oral-lyn's spray is to the mouth.

    "We believe we have the most efficient device at this point that could be available to patients," she said.

    http://www.sentinelandenterprise.com/ci_6276363
  18. [verwijderd] 4 juli 2007 14:14

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    dat is nog maar het begin Bonnie, het is een 18 maand keosrdoel, en er wordt hier alleen rekening gehouden met oralin in VS, en daarnaast ook niet de andere producten, zoalos Glucose Rapidspray etc.

    6$ is een voorzichtig koersdoel, maar laten we daar maar eerst heen gaan heh :)
  19. [verwijderd] 5 juli 2007 14:30

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Bird flu found in France
    12.11, Thu Jul 5 2007


    Three swans found in France died from the deadly H5N1 bird flu virus.

    France has increased its bird flu threat level from "moderate" to "high" after the positive tests.

    France is Europe's biggest poultry producer and has increased its precautions against bird flu after the disease was found in a several wild birds in Germany.

    The disease was also found in the Czech Republic last month.

    More than 30 countries have reported outbreaks in the past year, in most cases involving wild birds such as swans.

    Globally, the H5N1 virus has killed nearly 200 people out of over 300 known cases, according to the World Health Organisation. None of the victims were from Europe.

    May 24: Bird flu found at Welsh farm

  20. [verwijderd] 5 juli 2007 14:30

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Germany raises bird flu alert - Summary
    Posted : Thu, 05 Jul 2007 12:19:00 GMT
    Author : DPA
    Category : Health
    News Alerts by Email click here )
    Create your own RSS

    Health News | Home




    Berlin - Germany on Thursday raised its risk-preventive measures for bird flu after 38 wild birds tested positive for the lethal H5N1 strain in the east of the country. The birds were among 100 found dead on an artificial lake between the states of Thuringia and Saxony-Anhalt.

    The alert was raised from "moderate" to "high," by the Friedrich Loeffler federal animal diseases institute, which carried out tests on the dead birds.

    Last week, wild swans, geese and ducks were found with H5N1 in Leipzig in the eastern state of Saxony and in the southern city of Nuremberg in Bavaria.

    French authorities also raised their alert to "high" on Thursday after three swans found dead in eastern France were found to be carrying the deadly H5N1 virus.

    Some 190 people around the world have died of bird flu since 2003, mainly through coming into close contact with infected poultry, according to the World Health Organization.

    Scientists fear the virus could mutate into a form easily transmissible between humans, which could touch off a global pandemic that would kill millions of people.

    Last year, bird flu was confirmed in 13 European Union member states: Germany, Austria, Denmark, Italy, Greece, Britain, the Czech Republic, Poland, Slovakia, Slovenia, Sweden, France and Hungary.

    A new outbreak was confirmed in the Czech Republic late last month. German officials said they believed the disease might have spread from there to Germany.

    Copyright © 2007 Respective Author



  21. [verwijderd] 5 juli 2007 17:47

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    This is a summary of the positive potential of GNBT and when significant events may be occurring to give us longs an idea of what to expect in the near future:

    1. TORC initiated a 12 month target price of $3.00 - $3.50
    back on 9/27/2006. That puts us at that price this
    September which is in 3 months!!!!! This is possible.
    2. Volunteers were selected for the Avian Flu Vaccine back
    in February of this year. We should be hearing
    something about the studies I would say in August which
    puts us at the 6 month mark. We know that this vaccine
    will be a success because Antigen Express knows their
    stuff with synthetic vaccines. Bird Flu is heating up
    again.
    3. Last year in August, Clinical Trials in Greece were
    initiated for the Prostate Cancer vaccine. So, we
    should hear something soon, I am estimating in August
    or September. So, you see, August and September are
    shaping up to be big months for GNBT. That is why
    TORC put a year's target of $3 - $3.50 back in Sept.
    of last year. We are almost there guys.
    4. Jesup and Lamont initiated coverage with a buy and
    price target of $3.25 back in February of this year.
    5. GNBT entered into a deal with the Chinese to study
    a Novel RNAI treatment for cancer back in March of this
    year. We should hear something at the 6 month mark
    which again puts us in September/October. You see
    how things are shaping up?
    6. BIG ONE: GNBT entered a licensing agreement for Oralyn
    with Leosons of the Middle East and approvals will be
    in line for Fall of 2007. Again September/October.
    This is the big Kahuna here guys.
    7. GNBT announced Middle Eastern distribution of Glucose
    Rapidspray back in April of this year. Revenues!!!!!
    8. GNBT announced the treatment of the first breast
    cancer patients in Phase II trials in May of this
    year. We should hear something in November. Not
    that far off. After the blockbuster announcements
    I have mentioned above in Sept/Oct, now we will hear
    about these trials in November. Wow!!
    9. In May of this year, GNBT announced the launch of the
    two new OTC products. More revenues!!
    10. Rodman and Renshaw start coverage on GNBT with a
    price target of $6 over the next year. That could be
    as soon as January of 2008 like 6 months off.
    Things are looking good guys.
    11. Other things to consider: We should see some other
    South American approvals before the end of the year
    for Oralyn and GNBT will begin their Phase III
    studies probably in October. Sept/October is the
    time frame to be looking at for big changes!!!
    Hope this helps everyone as they are watching GNBT
    in the coming months.
    :))))))....will see
    h€$inz
3.572 Posts
Pagina: «« 1 ... 143 144 145 146 147 ... 179 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.018
AB InBev 2 5.501
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.675
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 265
Accsys Technologies 23 10.698
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 189
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.752
Aedifica 3 916
Aegon 3.258 322.852
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.893
Agfa-Gevaert 14 2.050
Ahold 3.538 74.339
Air France - KLM 1.025 35.047
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.041
Alfen 16 24.858
Allfunds Group 4 1.473
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.244
AMG 971 133.363
AMS 3 73
Amsterdam Commodities 305 6.690
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.007
Apollo Alternative Assets 1 17
Apple 5 382
Arcadis 252 8.776
Arcelor Mittal 2.033 320.714
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.302
Aroundtown SA 1 219
Arrowhead Research 5 9.740
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.108
ASML 1.766 107.439
ASR Nederland 21 4.486
ATAI Life Sciences 1 7
Atenor Group 1 491
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.673
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392